Alcoholic Liver Disease

• Acetaldehyde-mediated toxicity and oxidative stress: Ethanol is metabolized primarily by hepatic alcohol dehydrogenase (ADH) to acetaldehyde, which is further oxidized to acetate by aldehyde dehydrogenase (ALDH). Acetaldehyde is highly toxic and directly damages hepatocyte membranes, proteins, and DNA. The NADH-generating steps of this metabolism increase the hepatic NADH/NAD+ ratio, promoting lactate production (contributing to metabolic acidosis), inhibiting gluconeogenesis, and driving fatty acid synthesis and triglyceride accumulation. This metabolic imbalance is central to steatosis development. Additionally, chronic ethanol exposure upregulates cytochrome P450 2E1 (CYP2E1), which generates reactive oxygen species (ROS) during ethanol oxidation. These ROS cause lipid peroxidation, deplete antioxidant defenses (reduced glutathione, vitamin E), and activate inflammatory pathways. Acetaldehyde forms adducts with proteins (acetaldehyde-protein adducts), which are immunogenic and trigger innate immune responses.

• Lipopolysaccharide (LPS) translocation and TLR4 activation: Chronic ethanol increases intestinal permeability through tight junction disruption (claudin-2 downregulation, zonula occludens-1 loss) and dysbiosis (promoting gram-negative bacteria). This facilitates bacterial translocation and increased portal blood endotoxemia (LPS). LPS binds to Toll-like receptor 4 (TLR4) on hepatic macrophages (Kupffer cells), triggering nuclear factor-kappa B (NF-κB) activation and massive production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). TNF-α is a cardinal mediator of hepatocyte apoptosis and necrosis in ALD; TNF receptor-mediated activation of caspase cascades leads to programmed cell death. This LPS-TLR4 pathway is considered essential for the transition from simple steatosis to alcoholic hepatitis.

• Hepatic stellate cell (HSC) activation and fibrogenesis: Hepatocyte injury releases damage-associated molecular patterns (DAMPs) and pro-inflammatory mediators that activate quiescent HSCs into proliferative, fibrogenic myofibroblasts. Additionally, acetaldehyde, oxidative stress, and TGF-β directly promote HSC transdifferentiation. Activated HSCs produce excessive extracellular matrix (collagen I and III, fibronectin, proteoglycans), replacing normal hepatic architecture. This excessive collagen deposition increases hepatic stiffness, compromises hepatocellular function, and impedes blood flow, perpetuating a cycle of chronic inflammation and fibrosis. Over time, this leads to cirrhosis with portal hypertension.

• Mitochondrial dysfunction and hepatocyte autophagy impairment: Ethanol and acetaldehyde directly damage hepatocyte mitochondria, reducing ATP production, impairing β-oxidation of fatty acids, and promoting further ROS generation. Chronic ethanol impairs selective autophagy (mitophagy), reducing clearance of damaged organelles. Autophagy is also dysregulated, with both inhibition of protective autophagy and uncontrolled autophagic flux leading to hepatocellular dysfunction and death.

• Adaptive immune and microRNA dysregulation: Beyond innate immunity, chronic ALD drives pathological adaptive immune responses with increased hepatic T-cell infiltration (Th1 and Th17 cells) and antibody production against modified self-antigens (acetaldehyde-protein adducts, S100 proteins). Ethanol dysregulates microRNA expression, particularly downregulation of miR-122 (which normally suppresses HCV replication and regulates lipid metabolism), further exacerbating steatosis. Dysregulation of miR-34a contributes to impaired cellular stress responses.

• Chronic ethanol consumption (primary requirement): The fundamental etiology is sustained, excessive alcohol intake. Critical thresholds for risk include >40 g/day (approximately 4 standard drinks daily) in women and >60 g/day in men sustained for ≥10 years, though significant individual variation exists. Notably, some individuals develop cirrhosis with lower consumption levels, while others tolerate higher amounts without significant liver disease, highlighting genetic susceptibility as a critical modifying factor. The pattern of drinking (continuous vs. binge) also influences risk; binge drinking promotes more severe inflammation than equivalent amounts consumed regularly.

• Genetic polymorphisms and metabolic susceptibility: ALDH2 polymorphisms (particularly the ALDH2*2 allele common in Asian populations) impair acetaldehyde metabolism, paradoxically reducing ALD risk by causing unpleasant flushing reactions that discourage drinking. Conversely, ADH1B and ADH1C variants that enhance ethanol metabolism to acetaldehyde increase risk. Patatin-like phospholipase domain-containing protein 3 (PNPN3) polymorphisms (particularly the I148M variant) significantly increase susceptibility to hepatic steatosis and progression to cirrhosis. Fatty acid binding protein 1 (FABP1) and superoxide dismutase 2 (SOD2) variants influence lipid metabolism and oxidative stress responses, modifying disease risk.

• Female sex and hormonal factors: Women develop more severe ALD at lower cumulative alcohol consumption than men, a phenomenon termed "increased biological vulnerability." Estrogen enhances gut permeability and LPS translocation, increases CYP2E1 activity, and impairs hepatic antioxidant defenses. Hormonal cycles may modulate disease progression. Menopausal status and hormone replacement therapy influence risk profiles.

• Obesity and metabolic syndrome: Concurrent obesity accelerates ALD progression through multiple mechanisms: increased intestinal permeability, higher hepatic lipid accumulation, enhanced oxidative stress, and increased pro-inflammatory adipokine production (TNF-α, IL-6 from adipose tissue). The overlap of alcoholic and non-alcoholic fatty liver disease is increasingly recognized and worsens outcomes.

• Hepatitis C virus (HCV) coinfection: HCV/alcohol coinfection synergistically accelerates fibrosis progression and cirrhosis development. HCV core protein promotes oxidative stress and impairs lipid metabolism; combined with ethanol, this creates a particularly aggressive phenotype. HCV genotype 3 is associated with greater steatosis.

• Hepatitis B virus (HBV) coinfection: Similar to HCV, HBV coinfection with chronic alcohol use promotes accelerated liver disease and increased risk of hepatocellular carcinoma.

• Nutritional deficiencies: Chronic alcoholism frequently involves poor dietary intake and malabsorption, leading to deficiencies in thiamine (vitamin B1), folate, vitamin A, and vitamin E. These deficiencies impair hepatic antioxidant defense, promote lipid peroxidation, and exacerbate inflammation. Thiamine deficiency is particularly critical, causing Wernicke encephalopathy in susceptible individuals.

• Immunological factors and genetic variants in immune pathways: Variations in TNF-α gene promoter (−308 G/A polymorphism) and interleukin-10 influence inflammatory intensity. Lysyl oxidase-like 4 (LOXL4) variants affect collagen cross-linking and fibrosis progression.

• Smoking: Concurrent tobacco use enhances oxidative stress and inflammatory responses, worsening ALD progression through increased CYP2E1 activity and reduced antioxidant reserves.

Early-stage disease (hepatic steatosis and mild-moderate alcoholic hepatitis)

• Asymptomatic steatosis: Many patients with fatty liver have no symptoms; disease is discovered incidentally on imaging or through elevated liver enzymes. The liver may be slightly enlarged on palpation but otherwise unremarkable clinically.
• Non-specific symptoms: Fatigue, malaise, and mild abdominal discomfort may be present. These are often attributed to alcohol intoxication or withdrawal rather than hepatic pathology.

Acute alcoholic hepatitis presentation

• Right upper quadrant abdominal pain and tenderness: Reflects hepatocyte necrosis, inflammation, and capsular stretch. Pain is often exacerbated by eating fatty foods, though in ALD it persists regardless of dietary intake.
• Jaundice: Appears when hepatocellular injury and cholestasis severely impair bilirubin metabolism and excretion; hyperbilirubinemia (predominantly direct) results in visible yellowing of sclera and skin typically occurring within days to weeks of heavy drinking.
• Fever and systemic inflammation: Reflects the intense inflammatory response with elevated TNF-α and IL-6; temperature elevation is common in alcoholic hepatitis and can indicate superimposed bacterial infection or hepatic necroinflammation.
• Nausea, vomiting, and anorexia: Result from hepatocyte cytokine production, portal hypertension, and gastric mucosal irritation from alcohol; severe vomiting may precipitate variceal bleeding.
• Hepatomegaly: The enlarged, tender liver is firm or nodular, reflecting steatosis, inflammation, and early fibrosis. The liver edge becomes palpable below the right costal margin.

Advanced cirrhotic disease (chronic complications manifestations)

• Ascites: Results from portal hypertension (increased hydrostatic pressure in splanchnic circulation) combined with decreased plasma albumin synthesis and renal sodium retention; manifests as abdominal distention, increased abdominal girth, and fluid wave on examination. Ascites signals decompensated cirrhosis and carries grave prognostic implications.
• Variceal hemorrhage: Develops from portal hypertension causing esophageal varices; presents with hematemesis (bright red blood or "coffee-ground" emesis), melena, and acute hemorrhagic shock. This is a life-threatening complication requiring emergency management.
• Hepatic encephalopathy: Elevated ammonia and other neurotoxic substances impair cerebral function; manifests as altered mental status ranging from subtle personality changes and cognitive slowing to confusion, asterixis ("liver flap"), and coma. May be precipitated by infection, variceal bleeding, or medication use.
• Hepatorenal syndrome: Progressive renal dysfunction in advanced cirrhosis due to severe splanchnic vasodilation and renal vasoconstriction; presents with oliguria, rising creatinine (often with preserved urinary sodium excretion <10 mEq/L), and ultimately acute kidney injury. Portends extremely poor prognosis.
• Spider angiomas and palmar erythema: Cutaneous manifestations of cirrhosis reflecting systemic estrogen excess (impaired hepatic estrogen metabolism); spider angiomas appear on trunk and upper extremities, while palmar erythema affects the thenar and hypothenar eminences.
• Gynecomastia and testicular atrophy: Result from altered estrogen-androgen balance due to impaired hepatic steroid metabolism; reflect advanced cirrhosis and poor hepatic synthetic function.
• Coagulopathy and bleeding: Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X) and other coagulation proteins manifests as easy bruising, epistaxis, and prolonged PT/INR.

Important clinical variants and presentations

• Asymptomatic elevated transaminases: Some individuals present with only laboratory abnormalities discovered on screening, emphasizing the need for structured history regarding alcohol use.
• Fulminant hepatic failure: Rare but catastrophic, presenting with rapid deterioration, severe coagulopathy (INR >1.5), and encephalopathy; mortality exceeds 80% without transplantation.
• "Superimposed" acute hepatitis on chronic cirrhosis: Patients with known cirrhosis may present with acute decompensation triggered by a drinking binge or infection, manifesting with rapid onset jaundice and hepatic decompensation.

Clinical history and risk assessment

• Obtain comprehensive alcohol use history documenting quantity (standard drinks/day), duration, pattern (continuous vs. binge), and timing of last drink. Use validated instruments: AUDIT (Alcohol Use Disorders Identification Test) score ≥8 suggests hazardous drinking; CAGE questionnaire (2 positive answers = 89% sensitivity for alcoholism). Critically, patients frequently underreport consumption; corroborate with family members when possible.
• Document comorbidities: viral hepatitis status, obesity, metabolic syndrome, smoking, and medication use (especially hepatotoxic drugs).

Laboratory findings (diagnostic and prognostic)

• Transaminases (ALT/AST): In ALD, AST typically exceeds ALT (AST/ALT ratio >2 is characteristic and helps differentiate ALD from NAFLD and viral hepatitis, where ALT usually ≥ AST). In mild disease, elevations may be modest (1.5-3× upper normal limit); severe hepatitis can produce marked elevation (up to 10-20× normal). Degree of elevation does not correlate with severity of liver injury—some patients with cirrhosis have near-normal transaminases.
• Alkaline phosphatase and GGT: Elevated (typically 2-5× normal) reflecting cholestasis and hepatic inflammation. GGT elevation is sensitive but not specific for alcohol use; however, isolated GGT elevation with mild transaminase elevation in a patient with alcohol history strongly suggests ALD.
• Bilirubin: In uncomplicated steatosis, bilirubin is normal. In hepatitis, elevated total and direct (conjugated) bilirubin reflects hepatocellular injury and cholestasis; bilirubin >5 mg/dL in acute hepatitis is associated with poor prognosis.
• Albumin and PT/INR: Serum albumin <3.0 g/dL reflects impaired hepatic synthetic function and correlates with cirrhosis and poor outcomes. Prothrombin time (PT) prolongation or INR >1.5 without correction by vitamin K indicates impaired synthesis of vitamin K-dependent factors and is a criterion for fulminant failure. These are the most sensitive markers of hepatic decompensation.
• Thrombocytopenia: Platelet count <150,000/μL suggests cirrhosis with portal hypertension and splenic sequestration; progressive thrombocytopenia predicts bleeding risk.
• Ammonia: Elevated venous or arterial ammonia (>50 μmol/L) supports hepatic encephalopathy diagnosis, though ammonia level does not perfectly correlate with encephalopathy severity and is not routinely measured.
• Lipid profile: Hypertriglyceridemia (>500 mg/dL) is common in ALD due to increased VLDL synthesis from excess acetyl-CoA; hypercholesterolemia may also occur.

Imaging assessment

• Ultrasound: First-line imaging modality. Reveals hepatic steatosis as diffuse hyperechogenicity ("bright liver"), which is reversible. In cirrhosis, demonstrates nodular liver contour, heterogeneous echotexture, and stigmata of portal hypertension (splenomegaly, ascites, portal vein enlargement >13 mm, recanalization of umbilical vein). Ultrasound has limited sensitivity for distinguishing fibrosis stages and cannot reliably different

Immediate stabilisation (acute alcohol-associated hepatitis)

• Thiamine before any glucose-containing fluid: ethanol-related thiamine depletion makes carbohydrate loading precipitate Wernicke encephalopathy; give parenteral thiamine, then folate and other B vitamins.
• Withdrawal prophylaxis: benzodiazepines with symptom-triggered (CIWA-Ar) dosing; prefer agents without extensive oxidative hepatic metabolism (lorazepam) in cirrhosis.
• Screen aggressively for infection (blood, urine, diagnostic paracentesis) before immunosuppression — occult sepsis is common and changes management.

Foundation of therapy (all stages, AASLD 2019 guidance and ACG 2018 guideline)

• Complete alcohol abstinence: the single intervention that improves survival at every stage; steatosis is largely reversible with abstinence.
• Pharmacotherapy for alcohol use disorder: baclofen is the agent with the most supportive data in decompensated cirrhosis; acamprosate may be used, while naltrexone and disulfiram are generally avoided in advanced liver disease because of hepatotoxicity/opioid-antagonist concerns.
• Aggressive nutritional support: high-calorie, high-protein enteral feeding; protein restriction for encephalopathy is obsolete. Replete zinc, magnesium, phosphate; watch for refeeding syndrome.

Severe alcohol-associated hepatitis

• Corticosteroids: prednisolone 40 mg daily for 28 days is recommended by AASLD/ACG for Maddrey discriminant function ≥32 or MELD above the severe-disease threshold, with or without encephalopathy. Prednisolone is favoured over prednisone since it requires no hepatic conversion.
• Lille score at day 7: a score indicating non-response identifies futility — stop steroids and shift to transplant evaluation/palliation.
• N-acetylcysteine has been used as a steroid adjunct in some centres; benefit is on short-term rather than clearly on long-term mortality.

Definitive management

• Liver transplantation: for decompensated cirrhosis and, per AASLD guidance, for carefully selected steroid-non-responders with severe alcoholic hepatitis; a rigid 6-month abstinence rule is no longer mandated, though psychosocial assessment and relapse-risk stratification are required.

Contraindicated / avoid

• Corticosteroids in active uncontrolled infection, GI bleeding, hepatorenal syndrome, or untreated viral hepatitis.
• Pentoxifylline is no longer recommended after the STOPAH trial showed no survival benefit.
• Hepatotoxic/nephrotoxic agents: NSAIDs (precipitate renal failure and variceal bleeding) and unrestricted acetaminophen dosing.

Emergencies — recognise immediately

• Variceal hemorrhage: portal hypertension decompresses through gastroesophageal collaterals that rupture. Hematemesis/melena with hemodynamic instability. Management per AASLD portal hypertension guidance: volume resuscitation with restrictive transfusion, vasoactive splanchnic vasoconstrictor (octreotide), prophylactic antibiotics (ceftriaxone), and urgent endoscopic band ligation; TIPS for refractory bleeding.
• Spontaneous bacterial peritonitis (SBP): gut bacterial translocation into protein-poor ascites. Signalled by fever, abdominal pain, or unexplained encephalopathy/AKI; diagnostic paracentesis showing ascitic PMN ≥250/µL. Treat with a third-generation cephalosporin plus IV albumin to prevent hepatorenal syndrome (AASLD ascites guidance).
• Hepatorenal syndrome (HRS-AKI): extreme splanchnic vasodilation → renal hypoperfusion despite normal tubules; bland sediment, very low urine sodium, creatinine unresponsive to albumin challenge. Terlipressin plus albumin is FDA-approved; alternatives include norepinephrine or midodrine/octreotide with albumin.
• Alcohol withdrawal/delirium tremens: GABA/NMDA rebound; autonomic hyperactivity, hallucinations, seizures — mortality if untreated.
• Acute-on-chronic liver failure: a drinking binge or infection superimposed on cirrhosis produces multiorgan failure and very high short-term mortality.

Chronic complications

• Ascites and hepatic hydrothorax: portal hypertension plus hypoalbuminemia; SAAG ≥1.1 g/dL confirms a portal-hypertensive origin. Treat with sodium restriction and spironolactone plus furosemide.
• Hepatic encephalopathy: failure of ammonia detoxification and portosystemic shunting; asterixis. Lactulose first, rifaximin added for recurrence.
• Hepatocellular carcinoma: chronic inflammation/regeneration in cirrhosis; AASLD recommends ultrasound surveillance with or without AFP every 6 months in cirrhotics.
• Coagulopathy, thrombocytopenia, hypersplenism, and cirrhotic cardiomyopathy.
• Wernicke–Korsakoff syndrome from thiamine deficiency; Zieve syndrome — hemolytic anemia, hyperlipidemia, and jaundice after a binge.

Treatment-related

• Corticosteroids: opportunistic and bacterial infection (the main cause of steroid failure), hyperglycemia, GI bleeding.
• Over-diuresis: hyponatremia, azotemia, and precipitated encephalopathy.
• Lactulose: dehydration and hypernatremia from excessive stooling.

• AST:ALT >2 is the signature ratio: relative pyridoxine (B6) deficiency limits ALT synthesis and mitochondrial AST is released. A companion clue is AST rarely exceeding ~400–500 U/L — transaminases in the thousands point away from alcohol toward acetaminophen, ischemic hepatitis, or acute viral hepatitis.
• Histology buzzwords: Mallory–Denk bodies (damaged intermediate-filament keratin), ballooning degeneration, neutrophilic lobular infiltrate, and perivenular/pericellular "chicken-wire" fibrosis. Viral hepatitis, the classic distractor, gives a lymphocytic portal infiltrate.
• Maddrey discriminant function ≥32 is the trigger for corticosteroids — calculated from prothrombin time and total bilirubin. Recall that prednisolone, not prednisone, is used, and reassess with the Lille score on day 7 to decide whether to continue.
• The single best next step before treating steroids: look for infection and GI bleeding. An occult infection is the most-tested contraindication, and steroids in that setting worsen mortality.
• Thiamine always precedes dextrose in the malnourished drinker — glucose without thiamine precipitates Wernicke encephalopathy (confusion, ophthalmoplegia, ataxia).
• Pentoxifylline is the classic outdated distractor; STOPAH showed no survival benefit and AASLD/ACG no longer recommend it.
• The single most powerful intervention at any stage is abstinence — steatosis reverses, and even decompensated patients can recompensate. Baclofen is the AUD pharmacotherapy best supported in cirrhosis; avoid naltrexone in significant liver injury.
• Ascitic fluid rules: SAAG ≥1.1 g/dL = portal hypertension; PMN ≥250/µL = SBP, treat empirically with cefotaxime plus albumin without waiting for cultures.
• Macrocytosis with elevated GGT in a patient with normal B12/folate is a quiet exam hint at heavy alcohol use.